查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472356

左旋多巴市場：按形式、給藥途徑和分銷管道分類：2023-2032 年全球機會分析和產業預測

Levodopa Market By Form, By Route of Administration, By Distribution Channels : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3個工作天內

價格

預計到 2032 年，全球左旋多巴市場將從 2022 年的 16.554 億美元成長至 29.346 億美元，2023 年至 2032 年的複合年成長率為 6.1%。

左旋多巴市場-IMG1

左旋多巴，通常稱為左旋多巴，是一種在體內轉化為多巴胺的化學成分。多巴胺是大腦分泌的化學信使。多巴胺促進快樂、大腦功能和記憶過程。幾乎所有患者都接受左旋多巴治療，左旋多巴是一種多巴胺前體，可有效控制帕金森氏症 (PD) 的早期症狀。碳度巴通常與含左旋多巴的藥物合併使用，透過減少多巴胺的代謝來提高其療效。

由於醫療保健基礎設施投資增加、可支配收入增加以及新興市場獲得醫療保健的機會迅速增加，左旋多巴市場正在經歷顯著成長。此外，隨著新興國家加強醫療保健系統，用於治療帕金森氏症的左旋多巴等藥物的供應和價格正在增加。醫療保健服務的改善將提高診斷和治療的起始率，從而推動對左旋多巴的需求。此外，可支配收入的增加使個人能夠負擔得起基本藥物，從而促進市場成長。此外，這些因素的結合不僅擴大了患者基礎，也為左旋多巴市場的製藥公司創造了新的成長機會，特別是在醫療基礎設施發達的地區。然而，與左旋多巴相關的高成本是限制左旋多巴市場成長的主要因素之一。此外，它還限制了患者獲得這種治療帕金森氏症的重要藥物，特別是在醫療保健資源有限和低收入人群的地區。此外，左旋多巴的經濟問題阻礙患者尋求一致的治療或遵守規定的治療方案，導致疾病管理結果不佳。此外，高成本可能導致醫療保健預算緊張，限制報銷選擇，並抑制市場成長。此外，解決負擔能力障礙對於確保公平獲得左旋多巴並減輕對市場成長和患者照護的影響至關重要。

相反，藥物輸送系統的技術進步有望透過創新配方和替代給藥途徑提高左旋多巴療效和患者依從性，並有望推動市場成長。此外，醫療保健支出的增加，特別是在新興地區，增加了左旋多巴的可及性並推動市場成長。此外，新興市場加上人口老化，為市場滲透提供了開拓的潛力。此外，探索新配方和聯合治療的持續研究計劃和通路開發正在增強左旋多巴的市場前景。此外，支持性醫療保健政策和報銷框架確保了廣泛的可及性，提高的疾病意識和診斷率有助於市場成長。

相關人員的主要利益

  • 本報告定量分析了 2022 年至 2032 年左旋多巴市場分析的細分市場、當前趨勢、估計/趨勢和動態，並確定了左旋多巴市場的強大機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的力量。
  • 詳細分析左旋多巴市場細分將有助於確定市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前位置的清晰了解。
  • 該報告包括對區域和全球左旋多巴市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

此報告可進行客製化（需要額外費用和時間表）

  • 產品中所含原料分析（按百分比）
  • 投資機會
  • 科技趨勢分析
  • 按產品/細分市場分類的參與者市場區隔分析
  • 新產品開發/主要廠商產品矩陣
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 十字交叉細分市場分析 - 市場規模與預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • 主要參與者的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）
  • 客戶/消費者/原料供應商名單 - 價值鏈分析
  • 全球/區域/國家層級參與者的市場佔有率分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
  • 平均售價
  • 市場佔有率分析
  • 品牌佔有率分析
  • 貿易資料分析
  • 產品消費
  • 價值鏈分析
  • 監管指引
  • 關鍵監管分析
  • 贖回場景
  • 專利狀況

第4章 左旋多巴市場：依形式

  • 概述
  • 錠劑
  • 膠囊
  • 粉末
  • 液體

第5章 左旋多巴市場：依途徑

  • 概述
  • 口服
  • 胃腸外的

第6章 左旋多巴市場：依通路

  • 概述
  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

第7章 左旋多巴市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 有競爭力的儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Novartis AG
  • Merck and Co. Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Co.
  • Teva Pharmaceutical Industries Ltd.
  • Impax Laboratories Inc.
  • Pfizer Inc.
  • UCB SA
  • Sun Pharmaceutical Industries Ltd.
  • Mylan Nv
Product Code: A213646

The global levodopa market is anticipated to reach $2,934.6 million by 2032, growing from $1,655.4 million in 2022 at a CAGR of 6.1% from 2023 to 2032.

Levodopa Market - IMG1

Levodopa, commonly called L-Dopa, is a chemical building block converted into dopamine in the body. Dopamine is a chemical messenger secreted in the brain. It facilitates pleasure, brain function, and memory processes. Almost all patients get levodopa, a dopamine precursor that effectively controls Parkinson's disease (PD) symptoms in its early stages. Carbidopa is frequently used in combination with levodopa-containing medications to increase their efficacy by decreasing dopamine metabolism.

The levodopa market has been witnessing significant growth, owing to rise in investments in healthcare infrastructure, increase in disposable income, and surge in healthcare access in emerging markets. Moreover, as emerging economies bolster their healthcare systems, increase in availability and affordability of medications such as levodopa for Parkinson's disease management. Improved access to healthcare services translates into greater diagnosis rates and treatment initiation, consequently driving the demand for levodopa. Furthermore, increase in disposable income empowers individuals to afford essential medications, driving the market growth. In addition, the combination of these factors not only expands the patient pool but also creates new growth opportunities for pharmaceutical companies operating in the levodopa market, particularly in regions with evolving healthcare infrastructures. However, high cost associated with levodopa is one of the key factors restraining the growth of the levodopa market. Moreover, affordability issues limit patient access to this crucial medication for Parkinson's disease management, particularly in regions with limited healthcare resources and low-income populations. Furthermore, the financial problem of levodopa prevents patients from seeking consistent treatment or adhering to prescribed regimens, leading to suboptimal disease management outcomes. In addition, the high cost may strain healthcare budgets and limit reimbursement options, restraining market growth. Moreover, addressing the affordability barrier is imperative to ensure equitable access to levodopa and mitigate its impact on market growth and patient care.

On the contrary, increase in technological advancements in drug delivery systems promise to enhance levodopa's efficacy and patient adherence through innovative formulations and alternative administration routes are expected to drive the market growth. Furthermore, rise in healthcare expenditure, especially in developing regions, facilitates greater accessibility to levodopa, driving the market growth. In addition, emerging markets, coupled with increase in geriatric population, offer untapped potential for market penetration. Moreover, ongoing research initiatives and channel developments exploring novel formulations and combination therapies bolster levodopa's market prospects. Furthermore, supportive healthcare policies and reimbursement frameworks ensure widespread accessibility, while increase in disease awareness and diagnosis rates contribute to the market growth.

The key players operating in the levodopa market include Novartis AG, Merck & Co. Inc., Eli Lilly & Company, Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., Impax Laboratories Inc., Pfizer Inc., UCB SA, Sun Pharmaceutical Industries Ltd., and Mylan NV. In addition, the market players are increasingly focusing on adopting strategies such as collaborations and acquisitions to gain a competitive edge in the market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the levodopa market analysis from 2022 to 2032 to identify the prevailing levodopa market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the levodopa market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global levodopa market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Analysis of raw material in a product (by %)
  • Investment Opportunities
  • Technology Trend Analysis
  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • List of customers/consumers/raw material suppliers- value chain analysis
  • Market share analysis of players at global/region/country level

Key Market Segments

By Form

  • Tablets
  • Capsules
  • Powder
  • Liquid

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • United Arab Emirates
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Merck and Co. Inc.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Co.
    • Teva Pharmaceutical Industries Ltd.
    • Impax Laboratories Inc.
    • Pfizer Inc.
    • UCB SA
    • Sun Pharmaceutical Industries Ltd.
    • Mylan Nv

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. Average Selling Price
  • 3.6. Market Share Analysis
  • 3.7. Brand Share Analysis
  • 3.8. Trade Data Analysis
  • 3.9. Product Consumption
  • 3.10. Value Chain Analysis
  • 3.11. Regulatory Guidelines
  • 3.12. Key Regulation Analysis
  • 3.13. Reimbursement Scenario
  • 3.14. Patent Landscape

CHAPTER 4: LEVODOPA MARKET, BY FORM

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Tablets
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Capsules
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Powder
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Liquid
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Parenteral
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: LEVODOPA MARKET, BY DISTRIBUTION CHANNELS

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Other
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: LEVODOPA MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Form
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channels
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Form
      • 7.2.5.1.2. Market size and forecast, by Route of Administration
      • 7.2.5.1.3. Market size and forecast, by Distribution Channels
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Form
      • 7.2.5.2.2. Market size and forecast, by Route of Administration
      • 7.2.5.2.3. Market size and forecast, by Distribution Channels
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Form
      • 7.2.5.3.2. Market size and forecast, by Route of Administration
      • 7.2.5.3.3. Market size and forecast, by Distribution Channels
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Form
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channels
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Form
      • 7.3.5.1.2. Market size and forecast, by Route of Administration
      • 7.3.5.1.3. Market size and forecast, by Distribution Channels
      • 7.3.5.2. UK
      • 7.3.5.2.1. Market size and forecast, by Form
      • 7.3.5.2.2. Market size and forecast, by Route of Administration
      • 7.3.5.2.3. Market size and forecast, by Distribution Channels
      • 7.3.5.3. France
      • 7.3.5.3.1. Market size and forecast, by Form
      • 7.3.5.3.2. Market size and forecast, by Route of Administration
      • 7.3.5.3.3. Market size and forecast, by Distribution Channels
      • 7.3.5.4. Spain
      • 7.3.5.4.1. Market size and forecast, by Form
      • 7.3.5.4.2. Market size and forecast, by Route of Administration
      • 7.3.5.4.3. Market size and forecast, by Distribution Channels
      • 7.3.5.5. Italy
      • 7.3.5.5.1. Market size and forecast, by Form
      • 7.3.5.5.2. Market size and forecast, by Route of Administration
      • 7.3.5.5.3. Market size and forecast, by Distribution Channels
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Form
      • 7.3.5.6.2. Market size and forecast, by Route of Administration
      • 7.3.5.6.3. Market size and forecast, by Distribution Channels
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Form
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channels
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Market size and forecast, by Form
      • 7.4.5.1.2. Market size and forecast, by Route of Administration
      • 7.4.5.1.3. Market size and forecast, by Distribution Channels
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Market size and forecast, by Form
      • 7.4.5.2.2. Market size and forecast, by Route of Administration
      • 7.4.5.2.3. Market size and forecast, by Distribution Channels
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Form
      • 7.4.5.3.2. Market size and forecast, by Route of Administration
      • 7.4.5.3.3. Market size and forecast, by Distribution Channels
      • 7.4.5.4. South Korea
      • 7.4.5.4.1. Market size and forecast, by Form
      • 7.4.5.4.2. Market size and forecast, by Route of Administration
      • 7.4.5.4.3. Market size and forecast, by Distribution Channels
      • 7.4.5.5. Australia
      • 7.4.5.5.1. Market size and forecast, by Form
      • 7.4.5.5.2. Market size and forecast, by Route of Administration
      • 7.4.5.5.3. Market size and forecast, by Distribution Channels
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Form
      • 7.4.5.6.2. Market size and forecast, by Route of Administration
      • 7.4.5.6.3. Market size and forecast, by Distribution Channels
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Form
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channels
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Form
      • 7.5.5.1.2. Market size and forecast, by Route of Administration
      • 7.5.5.1.3. Market size and forecast, by Distribution Channels
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Form
      • 7.5.5.2.2. Market size and forecast, by Route of Administration
      • 7.5.5.2.3. Market size and forecast, by Distribution Channels
      • 7.5.5.3. United Arab Emirates
      • 7.5.5.3.1. Market size and forecast, by Form
      • 7.5.5.3.2. Market size and forecast, by Route of Administration
      • 7.5.5.3.3. Market size and forecast, by Distribution Channels
      • 7.5.5.4. South Africa
      • 7.5.5.4.1. Market size and forecast, by Form
      • 7.5.5.4.2. Market size and forecast, by Route of Administration
      • 7.5.5.4.3. Market size and forecast, by Distribution Channels
      • 7.5.5.5. Rest of LAMEA
      • 7.5.5.5.1. Market size and forecast, by Form
      • 7.5.5.5.2. Market size and forecast, by Route of Administration
      • 7.5.5.5.3. Market size and forecast, by Distribution Channels

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
  • 9.2. Merck and Co. Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
  • 9.3. Eli Lilly and Company
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
  • 9.4. Bristol-Myers Squibb Co.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
  • 9.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
  • 9.6. Impax Laboratories Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
  • 9.7. Pfizer Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
  • 9.8. UCB SA
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
  • 9.9. Sun Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
  • 9.10. Mylan Nv
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot

LIST OF TABLES

  • TABLE 01. GLOBAL LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 02. LEVODOPA MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. LEVODOPA MARKET FOR CAPSULES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. LEVODOPA MARKET FOR POWDER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. LEVODOPA MARKET FOR LIQUID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 07. LEVODOPA MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. LEVODOPA MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 10. LEVODOPA MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. LEVODOPA MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. LEVODOPA MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. LEVODOPA MARKET FOR OTHER , BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. LEVODOPA MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 20. U.S. LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 23. CANADA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 35. UK LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 36. UK LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. UK LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 44. ITALY LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 45. ITALY LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 54. CHINA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 55. CHINA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 56. CHINA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 61. INDIA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. INDIA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH KOREA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA LEVODOPA MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 82. UNITED ARAB EMIRATES LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 83. UNITED ARAB EMIRATES LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 84. UNITED ARAB EMIRATES LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA LEVODOPA MARKET, BY FORM, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 91. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 92. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 93. MERCK AND CO. INC.: KEY EXECUTIVES
  • TABLE 94. MERCK AND CO. INC.: COMPANY SNAPSHOT
  • TABLE 95. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 96. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 97. BRISTOL-MYERS SQUIBB CO.: KEY EXECUTIVES
  • TABLE 98. BRISTOL-MYERS SQUIBB CO.: COMPANY SNAPSHOT
  • TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 101. IMPAX LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 102. IMPAX LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 103. PFIZER INC.: KEY EXECUTIVES
  • TABLE 104. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 105. UCB SA: KEY EXECUTIVES
  • TABLE 106. UCB SA: COMPANY SNAPSHOT
  • TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 109. MYLAN NV: KEY EXECUTIVES
  • TABLE 110. MYLAN NV: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. LEVODOPA MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF LEVODOPA MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN LEVODOPA MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN LEVODOPA MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL LEVODOPA MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. IMPACT OF KEY REGULATION: LEVODOPA MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. LEVODOPA MARKET, BY FORM, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR TABLETS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR CAPSULES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR POWDER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR LIQUID, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. LEVODOPA MARKET, BY ROUTE OF ADMINISTRATION, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. LEVODOPA MARKET, BY DISTRIBUTION CHANNELS, 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF LEVODOPA MARKET FOR OTHER , BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. LEVODOPA MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 28. U.S. LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. CANADA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. MEXICO LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. GERMANY LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. UK LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. FRANCE LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SPAIN LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. ITALY LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF EUROPE LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. CHINA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. JAPAN LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. INDIA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH KOREA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. AUSTRALIA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF ASIA-PACIFIC LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. BRAZIL LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SAUDI ARABIA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. UNITED ARAB EMIRATES LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. REST OF LAMEA LEVODOPA MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: LEVODOPA MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022